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Abstract
Lactate measurement in the critically ill has been traditionally used
to stratify patients with poor outcome. However, plasma lactate
levels are the result of a finely tuned interplay of factors that affect
the balance between its production and its clearance. When the
oxygen supply does not match its consumption, organisms such as
man who are forced to produce ATP for their integrity adapt in
many different ways up to the point when energy failure occurs.
Lactate, being part of the adaptive response, may then be used to
assess the severity of the supply/demand imbalance. In such a
scenario, the time to intervention becomes relevant: early and
effective treatment may allow the cell to revert to a normal state, as
long as the oxygen machinery (i.e. mithocondria) is intact.
Conversely, once the mithocondria are deranged, energy failure
occurs even in the presence of normoxia. The lactate increase in
critically ill patients may therefore be viewed as an early marker of a
potentially reversible state.
Lactate in critical illness
The normal reference values for lactate are traditionally
considered 1 ± 0.5 mmol/l in normal patients and <2 mmol/l
in critically ill patients [1]. Since 1975, values above 2 mmol/l
but lower than 5 mmol/l have been separated from values
above 5 mmol/l, associated with acidemia, as different clinical
entities – referring to hyperlactatemia states in the former
situation as opposed to lactic acidosis in the latter situation
[2]. A further stratification, initially proposed by Cohen in
1976 [3], has been subsequently used according to the
presence (type A) or absence (type B) of ‘evident’ causes of
tissue hypoxia to explain the underlying cause of increased
lactate. Over the years, however, more sophisticated means
of assessing regional and even local perfusion have changed
the aforementioned classification into a more perfusion-
oriented vision. In fact, our increased ability to assess tissue
oxygenation clearly implies that measured plasma lactate
concentration is only a small window of a much more
complicated scenario.
Lactate as a clinical marker of hypoxia
As will be described, lactate is one of the intermediate
products that increase as a consequence of the rearrange-
ment of metabolism during hypoxia. As such, lactate has been
widely considered a marker of tissue hypoxia. There are
several examples of the increase of lactate in hypoxic
conditions [4,5]. Figure 1 shows our own experimental results.
The lactate increase is very fast, a matter of minutes, and is
proportional to the defect in the oxidative metabolism [6].
However, measured plasma lactate is the balance between
production and clearance. Liver failure does in fact influence
the kinetics of lactate increase [7].
It is also worth note that lactate is an intermediate compound
of normal metabolism. Erythrocytes, for instance, which are
equivalent to an organ weighing approximately 2500 g, are
obligatory anaerobes and ‘breathe’ via the lactate they
produce that is recycled from fatty acid oxidation in the liver.
Lactate, in this case, may be considered an energy shuttle
rather than a waste compound [8].
Outcome and stratification of severity
Lactate has been used as a marker in critically ill patients
since 1964 [9]. In 1970, Weil and Afifi clearly showed the
relationship between lactate concentration and outcome [10].
Several authors have subsequently confirmed those results
[11-15]. Interestingly, lactate measurements have also been
used to stratify patients. In fact, plasma lactate may be used as
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a tool to discriminate patients with or without hemodynamic
failure, a process similar to the early definition of type B lactic
acidosis (see earlier). Many of the papers dealing with the
oxygen consumption/oxygen delivery (VO2/DO2) dependency
have included such an approach [16-24].
Therapeutic response
Even more important, however, is the use of lactate
measurement as a guide to therapy.
A lactate fall after a volume challenge may reveal a preload-
based energy failure. An increase of lactate following a
dobutamine challenge test may imply that the oxygen
machinery is unable to cope with the new workload [25]. The
use of lactate to assess the efficacy of therapy has been
recently shown by Rivers and colleagues in their frequently
quoted paper [26], and is confirmed by routine clinical use of
lactate in many clinical settings such as emergency
departments, operating rooms or intensive care units.
Despite the encouraging scenario, however, there are pitfalls
for lactate as a clinical marker. Specimen collection, the
stability of stored samples, the metabolic effects of blood
cells or even technical problems may affect the interpretation
of lactate concentrations [27]. Moreover, there are situations
in which plasma lactate does not increase despite its local
formation (exclusion of the territory from perfusion) or in
which the lactate increase does not correspond to energetic
failure (neoplastic cells, intoxications, etc.). Nevertheless, we
think the use of lactate may be of great value for clinical
practice, as long as it is ‘interpreted’ over time within other
signs, symptoms and biophysical measurements.
In the following we will propose a research hypothesis
according to which an increase of lactate in critically ill
patients may be considered positive when supply
dependency occurs. To describe this hypothesis we will first
briefly cover the basics of adaptation to tissue hypoxia in
order to define ‘energy failure’. We will then discuss the role
of lactate measurements in the critically ill and the meaning of
time to intervention following energy failure.
Adaptation to hypoxia and energy failure
Apart from the easy to understand differences between the
fresh water turtle, the hibernating frog and man, there is one
major difference: the first two species are able to ‘conform’ to
oxygen deprivation, whereas man definitively needs oxygen to
‘regulate’ his whole life [28].
The so-called oxygen conformers shut down energy
expenditure by arresting transmembrane ion traffic [29]. The
energy required for pumping ions across the membrane and
against the electrochemical gradient is in fact a great amount of
the resting energy expenditure. Ion channel arrest is therefore
valuable in decreasing oxygen requirements. Notably, ion
channel arrest does not interfere with cell integrity.
Oxygen regulators, such as man, lack this possibility to shut
down energy expenditure. They are forced to consume
energy irrespective of its supply. Such an imbalance of supply
and demand drives the cascade of events that eventually
leads the cell to death in the absence of oxygen (i.e. energy
substrate) [28].
Man does not always die even in critical hypoxic situations,
however, implying that a certain amount of adaptation to
hypoxia is possible. Some of the mechanisms of adaptation to
acute hypoxia are now described.
Flow redistribution
Blood flows to distal organs according to simple physical
laws. Hagen Pousille’s law clearly shows that flow depends
on the pressure gradient from the initial to the distal point of
Figure 1
Quick response to lactate production following exposure of laboratory
animals to hypoxia. The panel on the top represents changes in arterial
oxygenation (PO2) when inspiratory fraction of oxygen (FiO2) is
decreased to 8%. Bottom panel shows corresponding lactate changes.590
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flow and on the length and size of the vessels (i.e.
resistances). Given an initial pressure (i.e. heart function and
vessel tone), the flow distributes according to the least
pressure encountered downstream. Basically this is the
background for flow distribution to organs, given the local
neural control of vessel size that translates into resistance to
flow. The vasoconstriction and/or vasodilatation of different
vessels in critical conditions therefore allows blood flow to
redistribute to first-line organs, the function of which is
necessary to maintain integrity of the whole body to survive.
This simple yet sophisticated possibility is one of the
fundamentals of adaptation to hypoxia.
Flow redistribution, by increasing the number of capillaries
per tissue unit, is also one of the cornerstone mechanisms of
an oxygen extraction ratio increase.
Partial oxygen ‘shut down’
Years ago many authors and clinicians spent much time
dealing with the so-called VO2/DO2 dependency [30]. This
dependency is defined as the critical point below which VO2
depends on DO2. The VO2/DO2 dependency may be viewed
as an adaptive mechanism: the organism, due to a lack of
energy, consumes less energy. Perhaps this state was for a
long time considered ‘bad’, but we may provocatively think of
it as ‘good’ (i.e. as a strategy to survive).
This phenomenon may be viewed as an adaptation, thus
assimilating man, at least in part, to oxygen conformers.
Metabolic rearrangement
Metabolic rearrangement is impressive. Our complicated
metabolic machinery, once the substrate for energy
production decreases or even ceases, shifts its pathways to
overcome the problem.
One of the most known and important metabolic rearrange-
ments is the Pasteur effect. Under a lack of oxygen, pyruvate
derived from the anaerobic conversion of glucose cannot enter
the Krebs’ cycle via acetyl-coenzyme A to produce energy. The
conversion of pyruvate to lactate, despite unfavorable
stechiometry, thus allows energy production without oxygen.
This is a major adaptive mechanism to survive hypoxia.
Meanwhile, a whole interplay of metabolic pathways favors
lactate utilization for gluconeogenesis in the liver [31],
decreases glucose oxidation via insulin resistance [32] and
even redirects the compartmentalization of glucose/lactate
metabolism between different types of cells within the same
organ [33].
Acid–base status
According to Stewart’s view, lactate production modifies the
strong ion difference thus influencing one of the determinants
of H+ concentration. The resulting addition of protons drives
the CO2 dissociation equation, CO2 + H2O ↔ H2CO3 ↔
HCO3
– + H+, to the left causing CO2 to dissolve (even if the
CO2 content does not change). Both CO2 and the protons
move the dissociation curve of hemoglobin to the right, thus
allowing a better transfer of oxygen to the tissue.
The influence of pH on the adaptive response, however, is
possibly even more important. Indeed, while extreme values
of acidemia (perhaps below 7.2) interfere with hemodynamic
stability, a pH value lower than normal is somewhat essential
for adaptation. In fact, while there are tissues whose
metabolic rearranged pathways need lactate as an
intermediate metabolite to survive [34], the production of
lactate itself depends on the pH level [35].
Interestingly, the inhibition of phosphofructokinase by low pH,
decreasing the utilization of glucose, may serve as a strategy
to spare metabolic fuel avoiding rapid consumption and
exhaustion of glucose [36]. Moreover, the pH value controls
the rate of lactate uptake from blood by hypoxic skeletal
muscles [37].
Gene regulation
Metabolic pathways are driven by dissociation constants and
are under tight enzymatic control. However, as we are
increasingly learning, several kinds of ‘regulations’ (adaptive
not excluded) are under gene control.
Interestingly, possibly via the amount of reactive oxygen
species or directly via the mitochondria [38], cells sense
hypoxia and trigger the upregulation of a powerful factor,
hypoxia inducible factor-1 [39]. This inducible factor, which is
constitutively expressed and rapidly degraded in normoxic
conditions, is accumulated during hypoxia. The increased
protein stability can activate many of the aforementioned
mechanisms of adaptation, including the Pasteur effect [40].
Table 1 summarizes some of the cellular and systemic
responses in which hypoxia inducible factor-1 is involved, all
of which are of importance in preventing energy failure by
rearranging more favorable fuel utilization and by increasing
local oxygen delivery.
It is of note that absolute oxygen deprivation at the
mitochondria site is the trigger for cell apoptosis [39]. This is
another key factor in the genetic regulation of adaptation to
hypoxia, allowing programmed cell death (apoptosis) as
opposed to the much more harmful cell necrosis.
In conclusion, there are several mechanisms by which oxygen
regulators may initially adapt to an imbalance between energy
supply and energy demand. However, as shown in Fig. 2,
contrary to oxygen conformers, man is only able to cope with
an energy imbalance to a limited extent. Once the threshold
of adaptation is overcome, the obligate need for energy leads
to ‘energy failure’. This may be accounted for as an
unfavorable balance between ATP production and ATP
utilization (i.e. ATP turnover) according to the formula591
describing energy charge: Energy charge = ([ATP] +
0.5[ADP]) / ([ATP] + [ADP] + [AMP]). A ratio between 0.8
and 0.95 is considered normal to survive, implying normal
supply for ATP synthesis and structurally intact machinery (i.e.
mithocondria).
Energy failure, lactate and time-course of illness
As already mentioned, a hypoxic insult may lead an oxygen-
regulated organism to death or to survival according to its
ability to adapt to hypoxia. However, even for a given genetic
trait, an individual may undergo adaptation or energy failure,
depending on time. In fact, if one expressed ATP turnover
over time there may be a scenario in which forced
hypometabolism rapidly decreases ATP turnover, eventually
leading to cell death. On the contrary, a slow decrease of
ATP turnover may allow a much longer survival (Fig. 3).
In the acute setting, oxygen conformance is unlikely because
a decrease of VO2 is accompanied by an increase in lactate
levels. On the contrary, in the subacute settings, down-
regulation of some tissue metabolic activities is possible in
order to preserve more essential reactions [41]. There is also
evidence that oxygen conformance may exist in chronic
diseases in humans: Schumaker and colleagues reported
that VO2, determined indirectly by calorimetry, rapidly
increases after percutaneous valvuloplasty in patients with
severe aortic stenosis and cardiac cachexia [42].
When dealing with energy failure, time is the essence also
under a different perspective. In fact, there is a time window
in which the hypoxic cell, despite suffering, will revert to a
normal state if oxygen is supplied. After a time threshold,
however, an energy supply will be of no use. This time frame
is our therapeutic opportunity.
Let us consider hemorrhage as an example. Hemorrhage is
an acute preload hemodynamic impairment. Provided DO2 is
the product of stroke volume and heart rate (cardiac output)
times the oxygen content (respiratory function – arterial
oxygen content), the energy failure during hemorrhage is due
to a stroke volume deficiency that eventually leads to cell
hypoxia. In the presence of normal adaptation processes,
however, the cell may cope with hypoxia for a while. If preload
is restored meanwhile, once oxygen is back the cell will be
able to utilize it because the oxygen machinery (i.e.
mitochondria) is still intact.
However, if the lack of oxygen persists, necrosis occurs and
organ failure emerges late during the course of illness. At that
time, even if an acid load due to cell lysis may persist, the
adaptive metabolic rearrangement that previously was
responsible for the increase of lactate (see earlier) my cease.
Plasma lactate may then decrease over time, provided
clearance is not impaired.
Similarly, an exaggerated aerobic glycolysis through Na+K+-
ATPase stimulation during septic shock may lead to
hyperlactatemia [43,44]. However, severe patients with poor
outcome have been shown to have mitochondrial dysfunction.
In fact, mediators such as nitric oxide may inhibit the
respiratory chain in the presence of normoxia or even
hyperoxia [45].
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Table 1
Responses to acute and/or chronic hypoxia in which hypoxia
inducible factor-1 is involved
Pathway References
involved Gene controlled of interest
Glycolysis Aldolase A–C [46,47]
Enolase 1
Glucose transporter 1–3
Glyceraldehyde phosphate dehydrogenase
Hexokinase 1–2
Lactate dehydrogenase A
Phosphofructokinase L
Pyruvate kinase 1-M
Erythropoiesis Erythropoietin [48]
Angiogenesis Vascular endothelial growth factor [49]
Vascular tone Endothelin-1 [50-52]
Hemeoxygenase-1
Nitric oxide synthase 2
Figure 2
Different responses of oxygen conformers and oxygen regulators to
oxygen deprivation. Once a threshold of adaptation is reached, oxygen
regulators undergo an imbalance between energy supply and energy
consumption that leads to ‘energy failure’.592
It thus seems that once oxygen machinery is out of order,
whether the initial insult was hemorrhage or sepsis, the
therapeutic opportunity is lost. This view may be applied to
the literature on the hemodynamic supranormal target. If we
consider the paper by Rivers and colleagues [26], it is clear
that their intervention was very early in the course of the
energy failure process and was very effective (see sections
on mixed venous saturation of oxygen and lactate changes
over time – few hours), as opposed to the late (third day in
the intensive care unit) and ineffective (see section on venous
saturation of oxygen) treatment by Gattinoni and colleagues
[25].
Conclusion
The metabolic fate of lactate in the body is under
sophisticated and finely tuned control. Many different
conditions may alter the balance between its production and
clearance. This per se is a limitation for the use of lactate as a
clinical marker in critically ill patients.
Nevertheless, when energy failure becomes relevant, lactate
measurement over time may be used as a metabolic marker
of energy failure. Contrary to what one may think, an increase
of lactate in critically ill patients in the presence of supply
dependency may be viewed as a positive feature, indicating
the presence of functioning adaptive metabolic pathways!
Increased lactate levels may be considered an early marker of
a potentially reversible state, possibly indicating that ‘there is
still room’ to boost fast intervention.
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